NMNAT2 and polyneuropathy: Together with the results presented here, this suggests that targeting SARM1 when protein translation is inhibited could be beneficial, in addition to prophylactic administration in predictable neurotoxic injuries, such as chemotherapy, or in rare human diseases that involve loss of or altered NMNAT2 function, such as rare polyneuropathies (Huppke et al., 2019).